The first artificial drug of humanwell is expected to go on sale in the second half of the year

Li Jie, chairman of Yichang humanwell, a subsidiary of humanwell pharmaceutical, said at the institutional research meeting on March 26 that the company's newly approved narcotic and analgesic drug, nabufine, is expected to go on sale in the second half of this year Li Jie said that at present, a new workshop of nabufine API is under construction, which will be completed in the second half of the year and pass GMP certification, and strive to achieve product marketing in the second half of the year Nabufine hydrochloride and nabufine hydrochloride injection are the exclusive varieties approved by Yichang humanwell at the end of December last year They are opiate receptor sedative psychoactive drugs, which are mainly used to relieve moderate to severe pain caused by various diseases They have been widely used in clinical practice in foreign countries, and the varieties are widely valued by securities institutions Industry insiders believe that after the launch of nabufine, in addition to improving the company's product line, it will also effectively resist the risk of narcotics price reduction.